News|Articles|November 17, 2026

FDA Grants Final Approval to Generic Binimetinib in BRAF-Mutant Melanoma, NSCLC

Fact checked by: Ariana Pelosci

Alembic’s binimetinib 15-mg and 45-mg tablets, given with encorafenib, received final FDA approval for BRAF-mutant melanoma and NSCLC.

The FDA has granted final approval to an abbreviated new drug application (ANDA) for binimetinib tablets in 15-mg and 45-mg strengths, according to a press release from Alembic Pharmaceuticals Limited.1

The generic product is considered therapeutically equivalent to the reference listed drug, Mektovi (binimetinib) tablets. Binimetinib is a kinase inhibitor indicated in combination with encorafenib (Braftovi) for patients with unresectable or metastatic melanoma harboring a BRAF V600E or V600K mutation, and for adult patients with metastatic non–small cell lung cancer (NSCLC) harboring a BRAF V600E mutation, as detected by an FDA-approved test.1,2

The drug’s developer was one of the first ANDA applicants to submit a substantially complete application with a paragraph IV certification for the 15-mg strength, and the sole first applicant to do so for the 45-mg strength. As a result, the company is eligible for 180 days of generic drug exclusivity for both strengths.

The final approval follows a tentative approval granted earlier this year for the 45-mg strength, as well as a prior tentative approval for the 15-mg strength.3

According to the prescribing information for the reference product, the recommended dose of binimetinib is 45 mg orally twice daily, approximately 12 hours apart, with or without food, in combination with encorafenib, for both the melanoma and NSCLC indications. The first dose reduction is to 30 mg twice daily, and the recommended dose for patients with moderate or severe hepatic impairment is 30 mg twice daily.2

Efficacy in Melanoma

Approval of the reference product in melanoma was supported by data from the randomized, active-controlled, open-label phase 3 COLUMBUS trial (NCT01909453), which enrolled 577 patients randomly assigned to receive binimetinib plus encorafenib (n = 192), encorafenib alone (n = 194), or vemurafenib (Zelboraf; n = 191). Compared with vemurafenib, the combination produced a median progression-free survival (PFS) of 14.9 months (95% CI, 11.0-18.5) vs 7.3 months (95% CI, 5.6-8.2; HR, 0.54; 95% CI, 0.41-0.71; P <.0001) and a median overall survival (OS) of 33.6 months (95% CI, 24.2-39.2) vs 16.9 months (95% CI, 14.0-24.5; HR, 0.67; 95% CI, 0.53-0.84). The objective response rate (ORR) was 63% (95% CI, 56%-70%) vs 40% (95% CI, 33%-48%), respectively, with a median duration of response (DOR) of 16.6 months (95% CI, 12.2-20.4) vs 12.3 months (95% CI, 6.9-16.9).2

In a 7-year update of the trial, the PFS rate was 21.2% with the combination vs 6.4% with vemurafenib, and the OS rate was 27.4% vs 18.2%.3

Efficacy in NSCLC

In NSCLC, the indication was supported by findings from the open-label, single-arm phase 2 PHAROS trial (NCT03915951), which included 98 patients with BRAF V600E–mutant metastatic NSCLC, of whom 59 were treatment naive and 39 were previously treated. Per independent radiology review, the ORR was 75% (95% CI, 62%-85%) in the treatment-naive population and 46% (95% CI, 30%-63%) in the previously treated population. The median DOR was not estimable (95% CI, 23.1-not estimable [NE]) in treatment-naive patients and was 16.7 months (95% CI, 7.4-NE) in previously treated patients. The disease control rate at 24 weeks was 64% (95% CI, 51%-76%) and 41% (95% CI, 26%-58%), respectively.2,3

Safety Considerations

Warnings and precautions in the reference product label include new primary malignancies, cardiomyopathy, venous thromboembolism, ocular toxicities including serous retinopathy, retinal vein occlusion, and uveitis, interstitial lung disease, hepatotoxicity, rhabdomyolysis, hemorrhage, and embryo-fetal toxicity. The label recommends assessing left ventricular ejection fraction before treatment, after 1 month, and every 2 to 3 months thereafter.2

In COLUMBUS, the most common adverse reactions (≥25%) with the combination were fatigue (43%), nausea (41%), diarrhea (36%), vomiting (30%), and abdominal pain (28%). Serous retinopathy occurred in 13.6% of patients. In PHAROS, the most common adverse reactions (≥25%) were fatigue (61%), nausea (58%), diarrhea (52%), musculoskeletal pain (48%), vomiting (37%), abdominal pain (32%), visual impairment (29%), constipation (27%), dyspnea (27%), rash (27%), and cough (26%). Investigators reported that the safety profile in NSCLC was consistent with that observed in melanoma.2,3

Before initiating treatment, BRAF mutation status should be confirmed using tumor tissue for melanoma and tumor tissue or plasma for NSCLC. Ongoing monitoring of cardiac, hepatic, and ophthalmologic function is recommended throughout therapy.3

References

1. Alembic Pharmaceuticals Limited receives USFDA final approval for binimetinib tablets. News release. Alembic Pharmaceuticals Limited. November 14, 2026. Accessed November 17, 2026. https://tinyurl.com/5xewnyw5

2. Mektovi (binimetinib). Prescribing information. Array BioPharma Inc; 2024. Accessed November 17, 2026. https://tinyurl.com/4nrfskje

3. Alembic Pharmaceuticals Limited announces USFDA tentative approval for binimetinib tablets, 45 mg. Press release. Alembic Pharmaceuticals Limited. June 19, 2026. Accessed November 17, 2026. https://tinyurl.com/zvvjz73c


Related to this article